Hot Stocks

The stock market changes from minute to minute, and what’s hot today may not be hot tomorrow. Our expert analysts spot hot stocks that are heating up before the crowd swoops in to bid prices higher, and our journalists sift through the noise to shine a light on trending investments -- in spaces ranging from quantum computing to marijuana stocks -- to determine whether they’re actually worth your time.

How The Activision Blizzard Purchase Helps Microsoft Stock

By Louis Navellier and the InvestorPlace Research Staff
Microsoft and MSFT stock will benefit from the Activision Blizzard deal, as multiple catalysts will help this purchase be very worthwhile.

StoneCo May Have Potential, But It Comes with Macroeconomic Risks

By Stavros Georgiadis, CFA, InvestorPlace Contributor
STNE stock is a risky fintech name. While StoneCo does provide revenue growth, the business is also subject to operating weakness.

Use Weakness as Opportunity with Affirm Holdings Stock

By Ian Cooper, InvestorPlace Contributor
In Q2 2022, the company more than doubled its gross merchandise volume (GMV) year over year. In fact, that number was up 115% to $4.5 billion.

Fast-Moving Upstart Stock Requires Patience After Earnings Pop

By Nicolas Chahine, InvestorPlace Contributor
UPST stock has left very little room for easy entry. Investors must be cautious and buy it on less obvious days than those with a big pop.

Don’t Get Burnt with Toast Stock as Profitability Remains Elusive

By David Moadel, InvestorPlace Contributor
TOST stock ran high post-IPO, but then dropped fast. Expect continued volatility as Toast struggles to find its financial footing.

Don’t Expect Skillz to Rise Until It Can Show Profits

By Mark R. Hake, CFA
Skillz will release Q4 earnings on Feb. 23, but don't expect SKLZ stock to move much higher until the company gets on track to make money.

Novavax Just Can’t Get it Together

By Mark R. Hake, CFA
Patient investors should wait for NVAX stock to hit another low or for the FDA to approve its Covid-19 vaccine before investing.

3 Desirable Drug Stocks With Very Promising Pipelines

By Larry Ramer, InvestorPlace Contributor
Drug makers with superb pipelines are likely to deliver great returns for long-term investors. Here are three drug stocks to consider.

Sofi Got Its Bank License, But the Stock Is Still in the Dumps

By Mark R. Hake, CFA
Sofi got its bank license, but the stock is still in the dumps signaling something's still wrong. SOFI stock might face headwinds with its banking operation, especially with its valuation at 3 times tangible book value.

Despite Hitting New Lows, Coinbase Has a Promising Future

By Vandita Jadeja
Coinbase is trading close to the 52-week low, but this is a good chance to add COIN stock to your portfolio before it reports Q4 earnings.

High-Risk, High-Reward Vinco Ventures Stock Is Not for the Faint of Heart

By Louis Navellier and the InvestorPlace Research Staff
Despite its unanswered questions, traders with a high risk tolerance may still want to keep BBIG stock on their radar.

Nio Stock Should Trade Sideways as its Earnings Period Approaches

By Alex Sirois, InvestorPlace Contributor
NIO stock remains a strong bet for the long-term, but that doesn't matter in the face of the current economic environment.

7 Stocks in the Crosshairs of Activist Investors 

By Will Ashworth, InvestorPlace Contributor
Stocks haven't performed well so far in 2022. That's given activist investors lots of possible opportunities. Here are seven to consider.

Zynga Stock Would Look Strong in Any Other Market

By Alex Sirois, InvestorPlace Contributor
ZNGA stock has fared well in these increasingly difficult times for tech stocks. There are multiple ways to play this.

Sundial Growers Must Show Investors Things Are Better, Not Just Different

By Chris Markoch, InvestorPlace Contributor
Sundial has more time to avoid delisting. But being granted extra time to avoid delisting isn't exactly a catalyst in any sense of the word.

How Palantir Stock Investors Should Approach Earnings

By Josh Enomoto, InvestorPlace Contributor
Palantir seems poised to deliver a strong fourth-quarter performance, but insiders dumping PLTR stock remains a worrying contradiction.

Why I’m Done With Novavax Stock

By Will Ashworth, InvestorPlace Contributor
Management is terrible at delivering on its promises and even good news has failed to translate into higher prices for NVAX stock.

Lucid Isn’t Worth $7 Billion More Than Nio

By Will Ashworth, InvestorPlace Contributor
Lucid has got a great looking first vehicle but LCID stock should not be worth more than Nio at this point in its development.

Patience Is Key When It Comes to Desktop Metal Stock

By Dana Blankenhorn, InvestorPlace Contributor
Desktop Metal has consolidated the 3D metal printing industry, but it has yet to prove it can make money at it. DM stock requires patience.
Load More Articles